PPARγ Agonists for Podocyte Protection in Glomerulonephritis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapeutic approaches for rapidly progressive glomerulonephritis (RPGN) primarily target the immune system, and there is a lack of understanding and treatment for the role of the PPARγ and Nrf2 pathways in this condition, which are crucial for maintaining podocyte tolerance to immune injury.

Innovation Solution

The use of PPARγ agonists or expression activators, such as thiazolidinediones, to target the PPARγ and Nrf2 pathways in podocytes to prevent or treat RPGN, demonstrating their role in maintaining glomerular tolerance to severe immune-complex mediated injury.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current immune system targeting therapies are used for RPGN, then immune suppression is achieved, but podocyte tolerance to immune injury is not maintained and crescent formation progresses

Engineering Contradiction:

Improvepodocyte tolerance to immune injuryVSAvoidcrescent formation and glomerular injury

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces PPARγ agonists as intermediary compounds that mediate protection between podocytes and immune injury. These agonists activate the PPARγ-Nrf2 pathway, which acts as a protective intermediary system that enhances podocyte tolerance without directly suppressing the immune system, thereby preventing crescent formation while maintaining physiological balance

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the therapeutic parameter from immune system targeting to podocyte pathway activation. By administering PPARγ agonists, the patent modifies the biochemical parameters within podocytes (activating PPARγ and Nrf2 pathways), which fundamentally alters the podocyte's response to immune injury and prevents crescent formation

Inventive Principle:

Principle #35Parameter changes

2Reliability

If PPARγ agonists are administered early in RPGN, then podocyte protection is maximized, but delayed administration reduces therapeutic efficacy

Engineering Contradiction:

Improvepodocyte protectionVSAvoidtherapeutic window

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent applies preliminary action by administering PPARγ agonists before severe crescent formation occurs. The therapy is most effective when given early in the disease course to prevent podocyte injury before irreversible damage and crescent formation take place, maximizing protective effects

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent implements preliminary anti-action by using PPARγ agonists to pre-protect podocytes against upcoming immune injury. The agonists activate protective pathways in advance, creating a defensive state in podocytes that resists subsequent immune-mediated damage

Inventive Principle:

Principle #9Preliminary anti-action

Data Source

PatentUS10034868B2Methods for the prevention and the treatment of rapidly progressive glomerulonephritis

Publication Date: 2018.07.31 INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)

AI summary

The present invention relates to the prevention and the treatment of rapidly progressive glomerulonephritis.